Literature DB >> 6095272

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

T J Wiktor, R I Macfarlan, K J Reagan, B Dietzschold, P J Curtis, W H Wunner, M P Kieny, R Lathe, J P Lecocq, M Mackett.   

Abstract

Inoculation of rabbits and mice with a vaccinia-rabies glycoprotein recombinant (V-RG) virus resulted in rapid induction of high concentrations of rabies virus-neutralizing antibodies and protection from severe intracerebral challenge with several strains of rabies virus. Protection from virus challenge also was achieved against the rabies-related Duvenhage virus but not against the Mokola virus. Effective immunization by V-RG depended on the expression of a rabies glycoprotein that registered proline rather than leucine as the eighth amino acid from its NH2 terminus (V-RGpro8). A minimum dose required for effective immunization of mice was 10(4) plaque-forming units of V-RGpro8 virus. beta-propiolactone-inactivated preparations of V-RGpro8 virus also induced high levels of rabies virus-neutralizing antibody and protected mice against intracerebral challenge with street rabies virus. V-RGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabies virus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095272      PMCID: PMC392104          DOI: 10.1073/pnas.81.22.7194

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Immunization schedules for the new human diploid cell vaccine against rabies.

Authors:  S A Plotkin; T J Wiktor; H Koprowski; E I Rosanoff; H Tint
Journal:  Am J Epidemiol       Date:  1976-01       Impact factor: 4.897

2.  Antigenic properties of rabies virus components.

Authors:  T J Wiktor; E György; D Schlumberger; F Sokol; H Koprowski
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  Complications of smallpox vaccination, 1968: results of ten statewide surveys.

Authors:  J M Lane; F L Ruben; J M Neff; J D Millar
Journal:  J Infect Dis       Date:  1970-10       Impact factor: 5.226

4.  An unusual case of human rabies thought to be of chiropteran origin.

Authors:  C D Meredith; A P Prossouw; H van P Koch
Journal:  S Afr Med J       Date:  1971-07-17

5.  A simple colorimetric method for determination of protein.

Authors:  S Bramhall; N Noack; M Wu; J R Loewenberg
Journal:  Anal Biochem       Date:  1969-10-01       Impact factor: 3.365

6.  Two African viruses serologically and morphologically related to rabies virus.

Authors:  R E Shope; F A Murphy; A K Harrison; O R Causey; G E Kemp; D I Simpson; D L Moore
Journal:  J Virol       Date:  1970-11       Impact factor: 5.103

7.  Laboratoty techniques in rabies: tissue culture methods.

Authors:  T J Wiktor
Journal:  Monogr Ser World Health Organ       Date:  1973

8.  In vitro evidence of cell-mediated immunity after exposure of mice to both live and inactivated rabies virus.

Authors:  T J Wiktor; P C Doherty; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

9.  Rabies virus glycoprotein. II. Biological and serological characterization.

Authors:  J H Cox; B Dietzschold; L G Schneider
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

10.  Immunogenicity of rabies virus inactivated by -propiolactone, acetylethyleneimine, and ionizing irradiation.

Authors:  T J Wiktor; H G Aaslestad; M M Kaplan
Journal:  Appl Microbiol       Date:  1972-05
View more
  70 in total

1.  Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells.

Authors:  J K Larson; L Otvos; H C Ertl
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.

Authors:  B Dietzschold; M Gore; D Marchadier; H S Niu; H M Bunschoten; L Otvos; W H Wunner; H C Ertl; A D Osterhaus; H Koprowski
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Identification of an immunodominant epitope within the phosphoprotein of rabies virus that is recognized by both class I- and class II-restricted T cells.

Authors:  J K Larson; W H Wunner; L Otvos; H C Ertl
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG.

Authors:  Jun Peng; Li Chen; Zheng-Gang Zhu; Ze-Rong Zhu; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins.

Authors:  Paulo H Verardi; Fatema H Aziz; Shabbir Ahmad; Leslie A Jones; Berhanu Beyene; Rosemary N Ngotho; Henry M Wamwayi; Mebratu G Yesus; Berhe G Egziabher; Tilahun D Yilma
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Comparison of representative strains of infectious hematopoietic necrosis virus by serological neutralization and cross-protection assays.

Authors:  H M Engelking; J B Harry; J A Leong
Journal:  Appl Environ Microbiol       Date:  1991-05       Impact factor: 4.792

7.  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.

Authors:  J F Rodriguez; R Janeczko; M Esteban
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

8.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

10.  Genomic characterization of a poxvirus isolated from a child.

Authors:  A Rösen; J Pilaski; G Darai
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.